Bavarian Nordic granted new European patent on modified vaccinia virus Ankara

The European Patent Organisation (EPO) has granted a patent to Bavarian Nordic which further strengthens its intellectual property position on MVA in Europe.

The new patent EP 1 420 822 belongs to the same patent family as the issued U.S. Patent No. 7,097,842. The European Patent is directed to Modified vaccinia virus Ankara (MVA) which abortively infects neonates used for inducing or enhancing the maturation of the immune system, and thus, for example, concerns the high risk group of the young with an immature immune system.

Peter Wulff, President and CEO said, "This granted patent reinforces our growing patent position on MVA also in Europe and adds further value to our MVA-BN(R) technology base for the development of new and improved vaccines, including vaccines for children."